BMS-986484

BMS-986484 is an investigational bispecific antibody being developed by Bristol Myers Squibb for the treatment of advanced solid tumors. The drug is currently in Phase 1 clinical trials as both a monotherapy and in combination with nivolumab (an anti-PD-1 antibody) for patients with locally advanced, unresectable, metastatic, or recurrent malignant tumors. These include non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN)[1][2][3][4][5]. While the precise mechanism of action has not been publicly disclosed, available sources suggest that BMS-986484 may be a bispecific antibody potentially targeting CD40 and FAP; however, this has not been officially confirmed[8][9]. The drug represents a new molecular entity within the antineoplastic class[4].